Navigation Links
Advanced Life Sciences Announces Third Quarter 2008 Financial Results
Date:11/6/2008

ngs with the Securities and Exchange Commission.

ADVANCED LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY

(A Development Stage Company)

September 30, December 31,

CONSOLIDATED BALANCE SHEETS 2008 2007

(Unaudited)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $7,766,597 $18,324,991

Grant receivable 32,006 -

Prepaid insurance 329,363 251,493

Prepaid clinical trial expenses - 926,168

Other prepaid expenses and deposits 211,874 140,359

Total current assets 8,339,840 19,643,011

PROPERTY AND EQUIPMENT:

Furniture and fixtures 237,907 221,417

Laboratory equipment 159,186 159,186

Computer software and equipment 253,851 242,707

Leasehold improvements 502,798 177,253

Total property and equipment - at cost 1,153,742 800,563

Less accumulated depreciation (717,249) (542,032)

Property and equipment - net 436,493 258,531

OTHER ASSETS:

Deferred financing costs 361,250 -

Other long-term assets 10,000 10,000

Total other assets 371,250 10,000

TOTAL ASSETS $9,147,583 $19,911,542

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES:

Accounts payable $273,140 $2,685,751

Accrued milestone payable 10,000,000 -

Accrue
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  23andMe, ... of Kate Black as Privacy Officer and ... federal, and state privacy laws as well as health ... regulatory team, she will be responsible for reviewing, updating ... customers in the U.S. and abroad. She joined the ...
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
(Date:2/26/2015)... CLEVELAND , Feb. 26, 2015 BioEnterprise ... biomedical companies have attracted more than $2 billion in ... from local and national investors, strategic sources, state – ... Over half of the $2 billion has been raised ... announcement comes on the heels of the BioEnterprise ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... ... ensure future crisis prevented. , ... Davos-Klosters, Switzerland (Vocus) Jan. 29, 2010 -- Agriculture is a game-changer that ... such as civil unrest, DuPont Chair and CEO Ellen Kullman told attendees ...
... , Data Demonstrating a 35% Overall Response ... in Patients with Relapsed or Relapsed/Refractory Waldenstrom,s Macroglobulinemia to ... Issue of the Journal of Clinical Cancer Research , ... Zentaris Inc. (Nasdaq: AEZS ; TSX: AEZ) (the ...
... , Jan. 28 RSB Spine, LLC, today ... the company,s 510(k) application to permit the marketing of its ... Executive Officer John A. Redmond said: "We are ... distributors two additional products to offer customers seeking greater options ...
Cached Biology Technology:DuPont Chair and CEO: Agriculture is Key to Global Economic Growth, Sustainability and Security 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 3Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 4Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 5
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... which occurs naturally in bacteria as Ralstonia eutropha ... is biodegradable and is not dependent on fossil resources, ... to replace petroleum-based plastics. New research reported in BioMed ... describes an alternative method of producing PHB in microalgae. ...
... a ,fertility switch, in a study published in Nature ... with infertility, while low levels make a woman more likely ... The findings have implications for the treatment of infertility and ... one in six women have difficulty getting pregnant and one ...
... East Asia have identified two genetic variants associated with ... the Wellcome Trust and the Agency for Science, Technology, ... responds to dengue infection. Dengue is globally the ... 100 million infections occurring annually. Symptoms range from mild ...
Cached Biology News:Faulty molecular switch can cause infertility or miscarriage 2First genome-wide association study for dengue identifies candidate susceptibility genes 2First genome-wide association study for dengue identifies candidate susceptibility genes 3
... Thrombin is a highly purified preparation qualified ... appropriate vectors. The preparation is functionally tested ... free of detectable contaminating proteases. Prepared from ... certified tests to be negative for HBsAg ...
... The nature of proteomics demands the detection ... superior performance of the AXIMA-CFRplus with improved ... 5 ppm) provides increased confidence in protein ... for enhanced sensitivity, automated sample target handling ...
... users requiring mass detection but not ... TOF Mass spectrometer is ideally suited ... for high performance mass analysis. ... analysis, protein detection, micro-satellite DNA characterization ...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
Biology Products: